Cytokine mRNA-based therapy alleviates dendritic cell and T cell paucity to eliminate aggressive pancreatic cancer in preclinical mouse models

Key Points

• Cytokine mRNA therapy effectively alleviates dendritic cell and T cell scarcity, targeting pancreatic cancer.
• Improvements in immune response can enhance cancer elimination rates in aggressive pancreatic cancer.
• Assessment of therapy in preclinical mouse models highlights its potential efficacy against pancreatic cancer.
• Further investigations in human models could validate the therapeutic approach and its broad applicability.